Clinical Trial Detail

NCT ID NCT01015833
Title Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

hepatocellular carcinoma

Therapies

Doxorubicin

Sorafenib

Age Groups: adult

No variant requirements are available.